Here's hoping - just think about how long Dr. Tefferi has been waiting to unveil a therapy that *works (beyond palliative) for this disease.
He got a lot of backlash when he introduced his preliminary data in 2013, and then had to work with the FDA when they put the trial on Hold. Now almost 3 years later (and decades of his career)... could be a banner moment for the good Doctor.
So you've taken it upon yourself to heap scorn on people that have invested in GERN and hope (dream) that it has an effective therapy with IMET? Why is the real question?
This is from the Collaboration Agreement PR:
Under the terms of the Collaboration Agreement, we and Janssen have created a joint governance structure, including joint development and steering committees and working groups, to oversee and manage worldwide regulatory, development and manufacturing work under the joint clinical development plan and promotional activities (assuming we exercise the U.S. Opt-In Rights) for imetelstat, with Janssen responsible for the operational implementation of those activities.
Good point - from reading comments from JNJ execs, it is clear that they prefer to have positive partnerships. Clearly this means some independence and support as to how the trials/data are communicated... so this may just be a subtle nod that JNJ is supporting Dr. Tefferi's efforts both in the lab and in the scientific community.
I personally am not too concerned or interested with short percentage.
I am extremely interested in the FDA approval process, and what Dr. Tefferi has to say at ASCO in June. I doubt he would take center stage at such a prestigious conference to announce bad news.
So Shoenfield, by your own logic, you are not a real long.
Another LOL achieved by Mainecoastlover AKA Frank and Boots*
*R.I.P. Frank and Boots, wishing you enjoyment in Kitty Heaven
OK if you say so, I'll take it.
Sooner or later none of those technicals will matter, FDA approval is rare indeed (just ask SRPT investors) and if/when it happens, technicals will be like dust in the wind.
Steady, rigorous and replicable science takes time, a lot of time, and that is either a point of frustration or an opportunity, based on your outlook. For me, I have been taking it as an opportunity, and all signals are that those actions will pay off, as IMET looks to be a winner, a big winner for both patients and (patient) investors.
I'm surprised these same posters, who claim to be long, are not equally excited and enthusiastic about the GERN pps bucking the trend of the market and IBB and moving into positive territory...
Actually I'm not surprised at all, as they are clearly liars and a sham.
Comical how several posters are just exuberantly posting about how low we can go when the market and GERN pps is sliding...
It's good entertainment while we wait for the steady and rigorous pace of cutting-edge, breakthrough science takes its course...